Organization (Industry)
A.Vogel B.V.
ClinicalTrials.gov lists A.Vogel B.V. as lead sponsor of 15 trials. It has 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers A.Vogel B.V.: 15 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (7)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Common Cold | 2 |
| COVID-19 | 1 |
| Hot Flashes | 1 |
| Occupational Stress | 1 |
| Parasomnias | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Echinaforce Chewable tablets | 2 |
| A. Vogels Sore Throat lozenges | 1 |
| Echinaforce tincture | 1 |
| Sage extract, 3400 mg , DER 1:17 | 1 |
| Saw palmetto berry extract | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=8) | 38% on time (n=8) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of medical research | 3 |
| Alternative therapies in health and medicine | 1 |
| FEBS letters | 1 |
| Frontiers in medicine | 1 |
| Frontiers in nutrition | 1 |
Showing 5 of 7 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2007-06-01 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| A.Vogel AG | Roggwil Tg, CH | EMA |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Daacro GmbH & Co. KG | Co sponsors trial with | 1 |
| Biochemical Laboratory of the Department of Psychobiology, University of Trier | Co sponsors trial with | 1 |
Latest dated events (19)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-04-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-03-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-03-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2021-11-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-11-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 19 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FOXH1 | Trial sponsor | Named in trial exclusion criteria |
| FOXH1 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.